Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Mar 12:2:35-40.

Pazopanib and anti-VEGF therapy

Harry A Drabkin  1
Affiliations
Review

Pazopanib and anti-VEGF therapy

Harry A Drabkin. Open Access J Urol. .

Abstract

Pazopanib (Votrient™, GlaxoSmithKline), a multi-kinase inhibitor with activity against VEGFR and other receptors, was recently approved by the FDA for the treatment of advanced renal cell carcinoma (RCC). Here, we review the history of its development, together with an overview of VEGF and its receptors and co-receptors. Results from selected clinical trial data in RCC and other malignant diseases are presented. Based on available evidence, pazopanib is an effective VEGFR inhibitor with demonstrable clinical activity in metastatic RCC and promising activity in other diseases. Like most kinase inhibitors, its activity is not restricted to VEGF receptors, which is reflected in its side-effect profile.

Keywords: VEGFR; pazopanib; renal cell carcinoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic showing neuropilin1/2, VEGFR1/2 and plexin A receptors/co-receptors and their various ligands. The neuropilins function as co-receptors for various VEGF ligands, whereas the plexins are co-receptors for Sema3s. Abbreviations: FGR, fibroblast growth factor; HGF, hepatocyte growth factor.
Figure 2
Figure 2
The structure of pazopanib (cmpd 13).
See this image and copyright information in PMC

References

    1. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133(2):275–288. - PMC - PubMed
    1. Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res. 2004;10(18 Pt 2):6367S–70S. - PubMed
    1. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev. 2008;8(8):592–603. - PMC - PubMed
    1. Woolard J, Wang WY, Bevan HS, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64(21):7822–7835. - PubMed
    1. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006;312(5):549–560. - PubMed

LinkOut - more resources